What is Malignant PEComa?
Malignant PEComa is a very rare type of cancer that arises from special cells called perivascular epithelioid cells. These cells are unusual because they show features of both muscle cells and pigment-producing cells. PEComas belong to a group of tumours known as mesenchymal tumours, meaning they arise from connective tissues such as muscle and blood vessel walls.
Most PEComas are benign, but malignant PEComa is the aggressive form. It can develop in different parts of the body, including the uterus, abdomen, retroperitoneum, kidney, liver, and soft tissues.
This tumour is strongly associated with abnormalities in the mTOR signaling pathway, which controls cell growth and survival. In some patients, it is linked to a genetic condition called Tuberous Sclerosis Complex, where mutations lead to uncontrolled activation of the mTOR pathway.
Incidence
Malignant PEComa is extremely rare. It affects adults more commonly than children and is seen more often in females, particularly when it arises in the uterus. Because of its rarity, exact incidence rates are not well established.
Symptoms
Symptoms depend on the location of the tumour. Many patients notice a slowly enlarging mass. If it develops in the abdomen, it may cause abdominal pain, fullness, or pressure symptoms. Uterine tumours may cause abnormal bleeding.
In advanced cases, if the tumour spreads to the lungs or liver, symptoms such as shortness of breath, weight loss, or fatigue may occur. Some cases are discovered incidentally during imaging for unrelated issues.
Diagnosis
Diagnosis begins with imaging such as CT scan or MRI, which may show a well-defined soft tissue mass. However, definitive diagnosis requires biopsy and microscopic examination.
Under the microscope, the tumour cells appear epithelioid and are arranged around blood vessels. Special immunohistochemical staining shows markers related to both melanocytic and smooth muscle differentiation. Molecular testing may reveal activation of the mTOR pathway or gene alterations associated with tuberous sclerosis.
Treatment
The primary treatment is complete surgical removal of the tumour. If the tumour is localised, surgery may be curative.
In advanced or metastatic cases, targeted therapy using mTOR inhibitors such as everolimus or sirolimus is often used, because the tumour growth is driven by mTOR pathway activation. Chemotherapy has limited effectiveness in many cases.
Prognosis
The prognosis depends on tumour size, spread, and cellular features. Large tumours with invasion or metastasis have a more aggressive course. However, the introduction of mTOR-targeted therapies has improved outcomes in advanced disease. Regular follow-up is essential due to the risk of recurrence.
You can help us with your donation:
Without a Ribbon is a charity that works hard to aid those who suffer from rare cancers. You can help our cause in a variety of ways: